How many analytes can be included in a multiplex panel?

The number of analytes is scoped per project based on platform capacity, sample volume, and multiplex compatibility. Common panels range from 3 to 50 analytes, and we can discuss your specific needs during consultation.

What validation standard do you follow?

We apply a fit-for-purpose validation framework that aligns with the intended context of use. Validation parameters include precision, accuracy, linearity, specificity, matrix effect, and stability. The depth of validation is defined during project scoping.

Can you work with our existing biomarker candidates?

Yes, we can develop and validate assays using your shortlisted biomarker candidates or perform discovery profiling to nominate new markers. We also accept pre-existing reagents and protocols for assay transfer.

What sample types are supported?

We routinely work with serum, plasma, urine, tissue lysates, cell lysates, and CSF. Other matrices can be assessed case by case. Minimal sample volume requirements are platform-dependent.

Do you provide statistical analysis for panel performance?

Yes, our deliverables include statistical evaluation such as ROC analysis, multivariate modeling, and cross-validation to assess panel discriminatory power and robustness.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Biomarker Panel Development & Validation

Biomarker Panel Development

We design and validate multiplex biomarker panels from discovery through fit-for-purpose qualification, delivering the performance data.

End-to-end panel design from multi-omics discovery to analytical validation
Fit-for-purpose qualification aligned with your intended context of use
Multiplex assays across protein, gene expression, and metabolite analytes
Rigorous precision, accuracy, and reproducibility documentation
Integrated bioinformatics for candidate prioritization and panel optimization

Scope your biomarker panel

Why validate a biomarker panel with us?

We combine assay development expertise with flexible validation tiers to match your project stage—from exploratory to regulatory-ready.

Custom multiplex design for 5–50+ analytes per panel
Platform-agnostic solutions: qPCR, LC-MS, MSD, and more
Transparent study reports with full QC and method characterization

Reproducible

Fit-for-Purpose

Scalable

Our approach

Systematic biomarker panel development from target nomination to validation

We apply a structured, evidence-driven workflow that integrates discovery data with rigorous analytical validation to produce panels you can rely on throughout your program.

Multi-Omics Biomarker Discovery

We leverage untargeted proteomics, metabolomics, and transcriptomics to identify candidate biomarker panels from your study matrices.

LC-MS/MS and high-resolution accurate-mass profiling for broad coverage
Gene expression analysis via RNA-seq or targeted qPCR
Machine-learning-based feature selection to build compact multi-analyte panels

Fit-for-Purpose Validation

Validation is scoped to your intended use—from analytical characterization to full qualification with predefined acceptance criteria.

Precision, accuracy, linearity, LLOQ/ULOQ determination
Specificity, matrix effect, and stability assessment
Robustness testing and inter-operator reproducibility

Quality by Design

Every panel is developed with predefined target product profiles, ensuring that analytical performance meets the requirements of your specific context of use.

Statistical Rigor

We apply appropriate statistical models—including ROC analysis, multivariate regression, and cross-validation—to evaluate panel discriminatory power and reduce overfitting.

Biological Interpretability

Biomarker candidates are mapped to known pathways and disease mechanisms, providing mechanistic context that strengthens the translational rationale for the panel.

Deliverables

What you receive with every biomarker panel project

Our deliverables are designed to give you full transparency into panel performance and enable smooth regulatory or publication handoff.

Data Deliverables

Raw instrument files and processed concentration/expression data
Validation report with summary statistics, precision, and accuracy tables
Panel composition and analyte-specific performance characteristics

Reporting & Support

Detailed method description including protocol and reagent documentation
Fit-for-purpose validation summary with acceptance criteria results
Scientific consultation for panel refinement and next-step strategy

Service scope

Customizable parameters for your biomarker panel project

Each project is scoped collaboratively; the table below outlines typical parameters we define during initial consultation.

Parameter	Typical Project Scope
Biomarker type	Proteins, peptides, metabolites, lipids, nucleic acids (mRNA, miRNA)
Platform	LC-MS/MS, qPCR/dPCR, MSD, ELISA, RNA-seq
Sample matrix	Serum, plasma, urine, tissue lysates, cell lysates, CSF
Number of analytes per panel	Determined during scoping; typical range 3–50 analytes
Validation tier	Exploratory qualification to fit-for-purpose (not GLP) per context of use
Assay format	Singleplex or multiplex (multiplex capacity platform-dependent)
Replicates & controls	Minimum 3 replicates, calibration curve, QC samples per run
Data analysis	Concentration normalization, statistical modeling, ROC analysis

Workflow

Our biomarker panel development process

We follow a structured five-step pipeline designed to ensure reproducibility and alignment with your project goals.

Project scoping & assay design

We review your biomarker candidates, intended context of use, sample availability, and desired validation level to define an actionable development plan.

Assay development & optimization

We select or develop the analytical method, optimize reagent conditions, calibrator concentrations, and sample preparation protocols for the target matrix.

Pre-validation characterization

Precision, accuracy, linearity, and limit of quantification are assessed in pilot runs to confirm the assay meets performance thresholds before full validation.

Full validation & qualification

We execute a fit-for-purpose validation protocol including specificity, matrix effect, carryover, dilution linearity, and stability across intended storage conditions.

Data analysis & reporting

All validation data are processed, statistically evaluated, and compiled into a comprehensive report that documents method performance and panel characteristics.

Applications

Where validated biomarker panels accelerate your program

Our panels support diverse research needs across drug development and translational studies.

Accurate disease classification

Multiplex panels for detecting disease presence or severity with defined sensitivity and specificity in relevant populations.

Identify early-stage disease signatures from minimally invasive samples
Support clinical trial enrichment strategies with validated classifiers

Predict disease progression

Panels that stratify patients by risk of progression, recurrence, or survival, independent of therapy.

Baseline biomarker levels correlate with long-term outcomes
Enable more precise endpoint assessment in clinical studies

Identify likely responders

Biomarker panels that predict which patients will benefit from a specific therapy, supporting precision medicine strategies.

Select biomarker-defined subpopulations for targeted trials
Evaluate mechanism-of-action linked predictive signatures

Monitor target engagement and response

Assays that measure drug-induced changes on biological pathways over time.

Track PD marker modulation in dose-escalation studies
Provide early proof-of-mechanism readouts

FAQ

Common questions about biomarker panel development & validation

Answers to frequent inquiries we receive from sponsors and research partners.

The number of analytes is scoped per project based on platform capacity, sample volume, and multiplex compatibility. Common panels range from 3 to 50 analytes, and we can discuss your specific needs during consultation.
We apply a fit-for-purpose validation framework that aligns with the intended context of use. Validation parameters include precision, accuracy, linearity, specificity, matrix effect, and stability. The depth of validation is defined during project scoping.
Yes, we can develop and validate assays using your shortlisted biomarker candidates or perform discovery profiling to nominate new markers. We also accept pre-existing reagents and protocols for assay transfer.
We routinely work with serum, plasma, urine, tissue lysates, cell lysates, and CSF. Other matrices can be assessed case by case. Minimal sample volume requirements are platform-dependent.
Yes, our deliverables include statistical evaluation such as ROC analysis, multivariate modeling, and cross-validation to assess panel discriminatory power and robustness.

Scientific Literature

References

So JBY, Kapoor R, Zhu F, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021;70(5):829-837. View on PubMed
Verschuren L, Mak AL, van Koppen A, et al. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. Nature communications. 2024;15(1):4564. View on PubMed
Zhang X, Zheng MH, Liu D, et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. Cell metabolism. 2025;37(1):59-68.e3. View on PubMed
Tosoian JJ, Zhang Y, Xiao L, et al. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. JAMA oncology. 2024;10(6):726-736. View on PubMed
Niu L, Thiele M, Geyer PE, et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nature medicine. 2022;28(6):1277-1287. View on PubMed
Llitjos JF, Carrol ED, Osuchowski MF, et al. Enhancing sepsis biomarker development: key considerations from public and private perspectives. Critical care (London, England). 2024;28(1):238. View on PubMed

Please kindly note that our products and services are for research use only.